减剂量(24 Gy)受累部位放疗联合利妥昔单抗治疗早期非胃黏膜相关淋巴组织淋巴瘤的前瞻性II期试验
这项前瞻性II期试验评估利妥昔单抗联合24 Gy受累部位放疗(ISRT)治疗早期非胃黏膜相关淋巴组织(MALT)淋巴瘤,旨在降低远处复发并改善长期生存。共入组60例患者,可评估疗效的55例中完全缓解率达100%,中位随访30.2个月仅1例远处复发,估计5年远处复发率为1.9%。全分析集2年和4年无进展生存率分别为98.0%和92.9%,方案集为100%和94.4%。
要点
- 利妥昔单抗联合24 Gy ISRT在早期非胃MALT淋巴瘤中完全缓解率达100%。
- 中位随访30.2个月仅1例远处复发,估计5年远处复发率1.9%。
- 治疗相关血液学毒性常见但可控,感染发生率23.3%。
核心结论
- 利妥昔单抗联合24 Gy ISRT在局部非胃MALT淋巴瘤中实现持久疾病控制,并可能通过NK细胞介导的免疫激活产生协同获益。
研究设计与样本
- 前瞻性II期试验,截至2025年10月共入组60例早期非胃MALT淋巴瘤患者,可评估疗效的方案集为55例。
主要发现
- 方案集完全缓解率为100%。
- 中位随访30.2个月,仅观察到1例远处复发,估计5年远处复发率为1.9%。
- 全分析集2年和4年无进展生存率分别为98.0%和92.9%,方案集分别为100%和94.4%。
- 治疗相关血液学毒性常见但可控,感染发生率为23.3%,包括1例需终止治疗的4级呼吸道感染。
- 免疫表型分析显示腮腺、甲状腺或纵隔受累与较高淋巴细胞比例相关(39.5% ± 16.4%,P = 0.012)。
临床怎么用
- 对于早期非胃MALT淋巴瘤,可考虑利妥昔单抗联合24 Gy ISRT以降低远处复发风险。
- 治疗期间需监测血液学毒性和感染,尤其注意呼吸道感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While involved-site radiotherapy (ISRT) is the standard first-line treatment in localized non-gastric mucosa-associated lymphoid tissue (MALT) lymphoma, the cumulative risk of distant relapse poses a persistent clinical challenge. We conducted a prospective phase II trial evaluating rituximab with 24 Gy ISRT, aiming to reduce distant relapse and enhance long-term survival. By October 2025, 60 patients with early-stage non-gastric MALT lymphoma were enrolled. Among the per-protocol efficacy-evaluable cohort (n = 55), the combined immunoradiotherapy regimen achieved a complete response rate of 100%. At a median follow-up of 30.2 months, only one distant recurrence was observed (estimated 5-year distant recurrence: 1.9%). In the full analysis set, 2- and 4-year progression-free survival rates were 98.0% and 92.9%, respectively, improving to 100% and 94.4% in the per-protocol set. Treatment-related hematologic toxicity was frequent but manageable. Infections were reported in 23.3%, including one grade 4 respiratory infection that necessitated treatment discontinuation. Immunophenotypic profiling revealed that parotid, thyroid, or mediastinal involvement correlated with higher lymphocyte proportions (39.5% ± 16.4%, P = 0.012). Post-treatment immunologic changes featured near-complete B-cell depletion and a compensatory expansion of NK cells. Overall, the combined immunoradiotherapy regimen demonstrated durable disease control in localized non-gastric MALT lymphoma, with potential synergistic benefit from NK cell-mediated immune activation. Trial registration: Chinese Clinical Trials Registry, ChiCTR2000036318; registered on Aug 22, 2020 (prospective).
引用
- Liu H, Cheng Y, Liu S, et al. Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial. Leukemia. 2026. PMID: 42463943. doi:10.1038/s41375-026-03059-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。